How to buy Regeneron Pharmaceuticals stock | 599.74

Regeneron Pharmaceuticals is a biotech company headquartered in New York. While it works on a number of drugs and diseases, it's most recently been in the news for REGN-COV2 — the experimental antibody cocktail.

The antibody cocktail is being studied as a possible treatment for the novel coronavirus. Most notably, it was reported that President Trump was given REGN-COV2 after his COVID-19 diagnosis. But Trump received the drug under a Compassionate Use request, which means it's not yet FDA cleared and is still highly experimental.

Whether or not this drug proves to be effective in treating the novel coronavirus may have a significant impact on Regeneron's stock prices. With so many companies working on COVID-19 cures, vaccines and prophylactics, it's a race to see which drugs are approved first — and which turn out to be the most successful.

How to buy shares in Regeneron Pharmaceuticals

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Regeneron Pharmaceuticals. Find the stock by name or ticker symbol: REGN. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Regeneron Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$599.74, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Regeneron Pharmaceuticals, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Regeneron Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has COVID-19 affected Regeneron’s stock price?

After news broke that President Trump had been given Regeneron’s experimental COVID-19 treatment, REGN-COV2, the company’s stock rose 7%. This increase brings the stock’s year-to-date gain to more than 60% as of early October.

Excitement over the company’s COVID-19 treatment is buffeting share prices, but REGN-COV2 has not yet been approved by the Food and Drug Administration (FDA). The treatment was administered to President Trump under a Compassionate Use request.

What’s REGN-COV2?

REGN-COV2 is Regeneron’s experimental COVID-19 treatment. It’s a combination of two antibodies designed to help the immune system recover from illness.

The treatment is still in clinical testing but reported encouraging results from its Phase 1/2/3 study. In this study, 275 trial patients were given REGN-COV2. Administration of the antibody cocktail resulted in a reduction in viral load and time to alleviate symptoms in non-hospitalized patients afflicted with COVID-19.

Side effects were reported in two patients, but those patients were taking placebos, according to Regeneron.

In July 2020, Regeneron signed a supply agreement for REGN-COV2 with the US government worth $450 million as part of the president’s Operation Warp Speed plan to develop COVID-19 treatments and vaccines.

How has coronavirus impacted Regeneron Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Regeneron Pharmaceuticals's share price has had significant positive movement.

Its last market close was USD$599.74, which is 32.78% up on its pre-crash value of USD$403.15 and 76.71% up on the lowest point reached during the March crash when the shares fell as low as USD$339.39.

If you had bought USD$1,000 worth of Regeneron Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$1,335.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,757.24.

Regeneron Pharmaceuticals share price

Use our graph to track the performance of REGN stocks over time.

Regeneron Pharmaceuticals shares at a glance

• Key figures

Information last updated 2020-11-25.

Latest market close	USD$599.74
52-week range	USD$328.125 - USD$664.64
50-day moving average	USD$568.0559
200-day moving average	USD$592.3193
Wall St. target price	USD$673.17
PE ratio	20.7636
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$27.286

Buy Regeneron Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Regeneron Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Regeneron Pharmaceuticals, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Regeneron Pharmaceuticals price performance over time

Historical closes compared with the close of $599.74 from 2020-10-16

1 week (2020-11-19)	16.52%
1 month (2020-10-27)	2.96%
3 months (2020-08-27)	-2.48%
6 months (2020-05-27)	10.24%

1 year (2019-11-26)	64.84%
2 years (2018-11-26)	69.81%
3 years (2017-11-24)	55.84%
5 years (2015-11-25)	6.77%

Is Regeneron Pharmaceuticals under- or over-valued?

Valuing Regeneron Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Regeneron Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Regeneron Pharmaceuticals's P/E ratio

Regeneron Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 21x. In other words, Regeneron Pharmaceuticals shares trade at around 21x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Regeneron Pharmaceuticals's PEG ratio

Regeneron Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0912. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regeneron Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Regeneron Pharmaceuticals's EBITDA

Regeneron Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$3.3 billion.

The EBITDA is a measure of a Regeneron Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Regeneron Pharmaceuticals financials

Revenue TTM	USD$9.2 billion
Operating margin TTM	33.76%
Gross profit TTM	USD$4 billion
Return on assets TTM	12.99%
Return on equity TTM	30.6%
Profit margin	34.14%
Book value	$96.011
Market capitalisation	USD$54 billion

TTM: trailing 12 months

Shorting Regeneron Pharmaceuticals shares

There are currently 2.2 million Regeneron Pharmaceuticals shares held short by investors – that's known as Regeneron Pharmaceuticals's "short interest". This figure is 7.1% down from 2.3 million last month.

There are a few different ways that this level of interest in shorting Regeneron Pharmaceuticals shares can be evaluated.

Regeneron Pharmaceuticals's "short interest ratio" (SIR)

Regeneron Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Regeneron Pharmaceuticals shares currently shorted divided by the average quantity of Regeneron Pharmaceuticals shares traded daily (recently around 862939.0438247). Regeneron Pharmaceuticals's SIR currently stands at 2.51. In other words for every 100,000 Regeneron Pharmaceuticals shares traded daily on the market, roughly 2510 shares are currently held short.

However Regeneron Pharmaceuticals's short interest can also be evaluated against the total number of Regeneron Pharmaceuticals shares, or, against the total number of tradable Regeneron Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Regeneron Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Regeneron Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0261% of the tradable shares (for every 100,000 tradable Regeneron Pharmaceuticals shares, roughly 26 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Regeneron Pharmaceuticals.

Find out more about how you can short Regeneron Pharmaceuticals stock.

Regeneron Pharmaceuticals's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Regeneron Pharmaceuticals.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Regeneron Pharmaceuticals's total ESG risk score

Total ESG risk: 22.33

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Regeneron Pharmaceuticals's overall score of 22.33 (as at 01/01/2019) is pretty good – landing it in it in the 27th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Regeneron Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Regeneron Pharmaceuticals's environmental score

Environmental score: 1.51/100

Regeneron Pharmaceuticals's environmental score of 1.51 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Regeneron Pharmaceuticals's social score

Social score: 13.94/100

Regeneron Pharmaceuticals's social score of 13.94 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Regeneron Pharmaceuticals's governance score

Governance score: 5.88/100

Regeneron Pharmaceuticals's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Regeneron Pharmaceuticals's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Regeneron Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Regeneron Pharmaceuticals has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Regeneron Pharmaceuticals, Inc was last rated for ESG on: 2019-01-01.

Total ESG score	22.33
Total ESG percentile	26.82
Environmental score	1.51
Environmental score percentile	2
Social score	13.94
Social score percentile	2
Governance score	5.88
Governance score percentile	2
Level of controversy	2

Regeneron Pharmaceuticals share dividends

We're not expecting Regeneron Pharmaceuticals to pay a dividend over the next 12 months.

Regeneron Pharmaceuticals share price volatility

Over the last 12 months, Regeneron Pharmaceuticals's shares have ranged in value from as little as $328.125 up to $664.64. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regeneron Pharmaceuticals's is 0.3968. This would suggest that Regeneron Pharmaceuticals's shares are less volatile than average (for this exchange).

Regeneron Pharmaceuticals overview

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Frequently asked questions

• What percentage of Regeneron Pharmaceuticals is owned by insiders or institutions?

  Currently 2.742% of Regeneron Pharmaceuticals shares are held by insiders and 89.239% by institutions.

• How many people work for Regeneron Pharmaceuticals?

  Latest data suggests 8,314 work at Regeneron Pharmaceuticals.

• When does the fiscal year end for Regeneron Pharmaceuticals?

  Regeneron Pharmaceuticals's fiscal year ends in December.

• Where is Regeneron Pharmaceuticals based?

  Regeneron Pharmaceuticals's address is: 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591

• What is Regeneron Pharmaceuticals's ISIN number?

  Regeneron Pharmaceuticals's international securities identification number is: US75886F1075

• What is Regeneron Pharmaceuticals's CUSIP number?

  Regeneron Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 75886F107